UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Samsung BioLogics to complete Biogen’s call option
Samsung BioLogics posted Tuesday that the transfer of assets related to Sam...
by Lee Han-soo
|
2018-11-06 10:45
라인
Will PharmAbcine be new force on KOSDAQ?
PharmAbcine, an immuno-oncology company, might be a promising biotech firm ...
by Nam Doo-hyun
|
2018-11-05 16:32
라인
Celltrion gets orders for Herzuma in France
Celltrion Healthcare, a subsidiary of Celltrion, said Friday that it has su...
by Lee Han-soo
|
2018-11-02 17:08
라인
Government to help Pharmicell develop therapy for acute kidney injury
Pharmicell said Friday that the Ministry of Health and Welfare has decided ...
by Lee Han-soo
|
2018-11-02 14:16
라인
SLS Bio registers patent for nanotechnology multiplex diagnostic in Europe
SLS Bio said it has registered a patent related to its nanotechnology multi...
by Lee Han-soo
|
2018-11-01 11:03
라인
CrystalGenomics to change molecular targeted therapy from injection to oral drug in trials
CrystalGenomics said it would change the form of an investigational molecul...
by Nam Doo-hyun
|
2018-10-30 10:52
라인
‘I will help make Korea original holder of anticancer drugs’
“Original technologies are important for national development. We will deve...
by So Jae-hyeon
|
2018-10-29 14:43
라인
‘Bio Solution’s value to rise on arthritis cell therapy’
Bio Solution will be able to drive up its market capitalization once it obt...
by Nam Doo-hyun
|
2018-10-25 16:30
라인
Samsung BioLogics posts ₩101.1 billion in Q3 sales
Samsung BioLogics said Wednesday that it recorded 101.1 billion won ($88.7 ...
by Lee Han-soo
|
2018-10-25 11:02
라인
CancerRop advances into Malaysian gene market
CancerRop said Wednesday that it has signed a cooperative agreement with Ca...
by Lee Han-soo
|
2018-10-24 17:49
라인
Celltrion releases clinical trial results for Remsima SC in EU and US
Celltrion has presented phase 1 and 3 clinical trials for Remsima SC, the s...
by Lee Han-soo
|
2018-10-24 16:47
라인
Will synthetic biology be vital in smart therapeutics?
Synthetic biology, which designs biological components and systems in new w...
by Nam Doo-hyun
|
2018-10-24 16:40
라인
Biotech shares tank amid nosediving of Seoul stocks
Biotech and pharmaceutical shares plunged on Tuesday, hurt mainly by the ov...
by Nam Doo-hyun
|
2018-10-24 11:35
라인
‘Antibody drug developer AbClon noteworthy’
AbClon, a developer of innovative antibody medicines, is likely to achieve ...
by Nam Doo-hyun
|
2018-10-22 14:49
라인
L&C BIO sets offering price at ₩24,000 for KOSDAQ debut
L&C BIO, a tissue engineering company, said on Friday that it has set its o...
by So Jae-hyeon
|
2018-10-22 14:12
라인
'Superbug' fears bring antibiotics developers under spotlight
Investors are paying keen attention to antibiotics developers amid growing ...
by Nam Doo-hyun
|
2018-10-22 11:53
라인
Celltrion, Samsung BioLogics named Fortune’s ‘Future 50’
Fortune, a U.S.-based multinational business magazine, has named Samsung Bi...
by Lee Han-soo
|
2018-10-19 16:34
라인
CancerRop launches unit to develop cell therapies
CancerRop established CancerRop Cell on Wednesday, a subsidiary to develop ...
by Lee Han-soo
|
2018-10-18 15:25
라인
Biogen, Samsung Bioepis announce European launch of Imraldi
Biogen and Samsung Bioepis said Tuesday they will launch Imraldi, the compa...
by Lee Han-soo
|
2018-10-17 17:28
라인
Bio stocks listed under ‘tech exception policy’ perform better
Biotech and medical companies that went public under the Korea Exchange’s “...
by Nam Doo-hyun
|
2018-10-15 12:27
-
이전
11
12
13
14
15
16
17
18
19
20
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top